M2 Presswire - Depomed Begins Dosing Patients in Phase 2 Trial For Gabapentin GR to Treat Menopausal Hot Flashes.
M2 PRESSWIRE-14 June 2007-ExplorationInvestor: Depomed Begins Dosing Patients in Phase 2 Trial For Gabapentin GR to Treat Menopausal Hot Flashes(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:14062007 Exploration Investor strives to provide you with outstanding market results. We will be your number one resource for all your small and large cap needs.
Related Results
GabapentinGabapentin withdrawalNew gabapentin genericIVAX Launches Gabapentin CapsulesBattle commences on generic gabapentin
While working to keep you in touch with market activity, we also will keep you updated on the latest press. Today we have identified, Depomed, Inc. (NASDAQ:DEPO) due to the attention they received after this recent corporate development. …
Read the rest of this article with a Free Trial at HighBeam Research.
